Sleep is not just one of the problems being managed in Long COVID — it is the medium through which most other interventions work. Pain sensitization, autonomic regulation, immune function, and cognitive capacity are all substantially modulated by sleep quality. A patient with chronically fragmented or non-restorative sleep will show limited responses to even well-targeted treatment for their other sub-syndromes. This is why sleep warrants early, active attention rather than being deferred until other problems are resolved.
The default clinical approach — sleep hygiene counseling plus a sedating medication — fails most of these patients not because it's wrong but because it's incomplete. It addresses one piece of a multi-component problem, and often not the most important piece.
The Core Problem: Non-Restorative Sleep
The thread that runs through most Long COVID sleep presentations is not insomnia or hypersomnia per se — it is sleep that does not restore. Patients describe waking after 8, 10, or 12 hours feeling no more rested than after 4. Duration is not the variable that needs optimizing; architecture is. The question is not how much sleep the patient is getting but whether the sleep they get is doing the physiological work it's supposed to do.
Most patients present in one of two patterns — often with overlap between them:
Mixed Insomnia Pattern
Difficulty initiating sleep, maintaining sleep, or both — typically with hyperarousal as the dominant feature. The pre-sleep state is characterized by cognitive activation, rumination, sympathetic nervous system overdrive, and an inability to disengage. This is not simply "not being able to fall asleep." The autonomic dysregulation common in Long COVID means many patients experience genuine physiological arousal at night — elevated resting heart rate, adrenaline-like sensations, racing thoughts that are difficult to interrupt voluntarily. Circadian phase delays (feeling most alert late at night, unable to wake before mid-morning) frequently co-occur and can be difficult to separate from the insomnia pattern clinically.
Hypersomnia Pattern
Extended sleep with no restoration. Patients can sleep 12–14 hours and wake feeling profoundly unrefreshed. This is physiologically distinct from insomnia and from normal fatigue — the capacity and desire to sleep are intact, but sleep is not doing the work. This may reflect post-viral effects on orexin/hypocretin signaling, hypothalamic dysregulation, or sleep architecture disruption that produces inadequate slow-wave sleep regardless of total duration. Sleep apnea should be considered and ruled out, as untreated obstructive apnea is one of the most common causes of non-restorative hypersomnia and is treatable. Central apnea or complex sleep-disordered breathing, sometimes associated with autonomic dysregulation, is less common but worth considering in refractory cases.
Parasomnias — vivid dreaming, nightmares, sleep paralysis, and REM sleep behavior disorder (acting out dreams) — occur at elevated rates post-COVID and may reflect brainstem involvement or sleep architecture disruption. When present, high-dose melatonin (3–12 mg) is the preferred first-line option; safety measures to prevent injury during episodes are a practical priority.
What Restorative Sleep Actually Requires
The glymphatic system — a network of perivascular channels through which cerebrospinal fluid flows during sleep to clear metabolic waste from brain tissue — is most active during slow-wave sleep and is substantially suppressed during waking. There is reasonable evidence that glymphatic flow is impaired in conditions involving poor sleep quality, and emerging interest in whether Long COVID-associated brain fog may partly reflect inadequate glymphatic clearance.
What this framework clarifies is why strong sedatives are often counterproductive as sleep aids in this population. Benzodiazepines, Z-drugs, and high-dose antihistamines do produce sedation — but sedation is not the same as restorative sleep architecture. These agents suppress slow-wave sleep and alter REM distribution, which may produce sleep duration without the glymphatic and consolidation processes that make sleep restorative. For a population where cognitive restoration during sleep is already compromised, trading architectural quality for sedation depth is a poor exchange. This is not an argument against all pharmacotherapy — it is an argument for choosing agents that support rather than suppress sleep architecture.
Barriers That Must Be Addressed First
The most important clinical insight in Long COVID sleep management is that sleep cannot be made restorative until the conditions that prevent restoration are addressed. Applying CBT-I or medication to a patient who is physiologically wired, in significant pain, or working a schedule incompatible with normal sleep architecture is unlikely to produce meaningful improvement — not because the interventions are wrong but because the ground isn't ready for them.
The barriers that most commonly need to be resolved before sleep work can succeed:
- Autonomic hyperactivation and adrenaline surges at night — Patients often describe a pattern of falling asleep adequately, then waking abruptly 1–3 hours later with palpitations, diaphoresis, and an adrenaline-like state they cannot reverse. This is a dysautonomia problem, not primarily a sleep problem, and it generally requires autonomic treatment before sleep intervention is effective.
- Rumination and cognitive hyperarousal — The hyperactivated state that prevents sleep onset in the mixed insomnia pattern is often resistant to behavioral techniques alone when the underlying autonomic and central sensitization burden is high. Addressing the adrenaline component first — with appropriate pharmacotherapy or autonomic stabilization — often makes behavioral techniques more tractable.
- Active pain and central sensitization — Sleeping in pain is nearly impossible to address with sleep-specific interventions. Migraine, widespread pain sensitivity, and allodynia disrupt sleep architecture independently of any insomnia mechanism. Pain management must be a parallel priority.
- Circadian schedule incompatibility — A patient on a night work schedule, an irregular shift schedule, or living in a household with unavoidable disruptions at their optimal sleep time cannot be expected to achieve restorative sleep regardless of what pharmacotherapy is prescribed. Acknowledging this constraint honestly — and working around it where possible — is more useful than optimizing medications in an incompatible environment.
A practical frame: If a patient is physiologically wired at bedtime, waking in adrenaline surges, or in too much pain to sleep comfortably, restorative sleep is not yet achievable regardless of how well the sleep-specific intervention is designed. The sequence matters: stabilize the autonomic and pain picture first, then work on sleep architecture.
Treatment: Behavioral First, Medications as Adjuncts
The evidence hierarchy in sleep medicine is clear: behavioral therapies have consistently outperformed pharmacotherapy in long-term outcomes for insomnia, and they do so without the architectural disruption associated with sedating agents. CBT-I, timed light therapy for circadian components, and fixed wake time are the interventions with the best data. They are also the ones most likely to produce durable improvement rather than tolerance and rebound.
Medications are useful — sometimes necessary — for specific components of the sleep picture. The selection principle is to choose agents that address a targeted problem without broadly suppressing sleep architecture. Low-dose tricyclics (amitriptyline, nortriptyline) have dual utility in both insomnia and central sensitization, and may be particularly well-suited when both are prominent. Trazodone is frequently used and generally reasonably well-tolerated. Melatonin at physiological doses (0.5–1 mg timed appropriately) addresses circadian components; at higher doses (3–12 mg) it has a role in parasomnias. Orexin receptor antagonists (suvorexant, lemborexant) suppress wake-promoting signaling rather than globally sedating — a mechanism more aligned with the goal of supporting natural sleep architecture.
The Migraine Connection
Central sensitization and sleep have a bidirectional relationship that is clinically significant. Poor sleep lowers the threshold for central sensitization, increases pain sensitivity, and reliably triggers migraine in susceptible individuals. Active central sensitization, in turn, fragments sleep through night pain, arousal responses to sensory stimuli, and disrupted sleep architecture. Treating one without addressing the other tends to produce partial responses at best. Agents with dual utility — low-dose tricyclics, some anticonvulsants — are worth considering when both are prominent, because they address both targets simultaneously rather than requiring separate medications for each.
What Improving Sleep Changes
The clearest signal that sleep is genuinely improving is that other sub-syndrome symptoms begin to shift. Orthostatic heart rate increments on the NASA Lean Test decrease, pain sensitivity improves, and cognitive clarity increases. Sleep is not just one outcome — it is a mediating variable for most of the others. When it moves, it tends to move the whole picture. This is why addressing it early and specifically, rather than waiting until other problems are controlled, tends to produce disproportionate downstream returns.
In the Long COVID Tracker app: The sleep screen captures nightly data including bedtime, wake time, sleep latency, night wakings, restlessness, and a 1–5 restorativeness rating. Goals are organized by timing (morning routine, daytime, evening, if you wake at night) and can be paused based on current capacity. Weekly trends help identify which sleep domains are improving and which may need additional attention.